Documentation, analysis, and stability notes.
Source-aware writing about COA interpretation, shipment and storage boundaries, and receiving-lab responsibility for research-use materials.
- Compound context
Semax in Canada: research identity, documentation, and regulatory context
A source-based guide to Semax identity as an ACTH-fragment peptide, its regulatory status (registered in Russia, not approved elsewhere), and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 19, 20266 min readRead - Compound context
Selank in Canada: research identity, documentation, and regulatory context
A source-based guide to Selank identity as a tuftsin-analogue peptide, its regulatory status (available in Russia, not approved elsewhere), and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 19, 20266 min readRead - Compound context
Kisspeptin-10 in Canada: research identity, documentation, and regulatory context
A source-based guide to Kisspeptin-10 identity as a kisspeptin fragment, its receptor biology, the Canadian regulatory context, and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 19, 20266 min readRead - Compound context
Tirzepatide in Canada: research identity, documentation, and regulatory context
A source-based guide to Tirzepatide identity, the critical distinction between a research-use material and the approved prescription drug (Mounjaro / Zepbound), and what a lot-specific CoA does and doesn't establish.
Jul 19, 20266 min readRead - Reference
Sourcing research peptides in Canada: CoA documentation, sterility, and domestic supply
What a Canadian laboratory can verify before ordering research-use peptides — lot-specific CoA records, sterility and vial-format claims, and what "domestic supply" does and doesn't change about documentation.
Jul 18, 20267 min readRead - Reference
Reading a multi-component peptide blend: documentation, identity, and ratios
A blend combines two or more sequences in one vial, and its documentation has to account for each. What a blend's Certificate of Analysis should confirm, how a name encodes proportions, and why lot matching matters more here.
Jul 18, 20266 min readRead - Reference
A peptide research glossary: CoA, HPLC, lyophilized, and other terms
Short, plain definitions of the core terms a Canadian laboratory meets when sourcing research-use peptides — what each one means on a listing or a certificate, with pointers to the deeper notes.
Jul 18, 20266 min readRead - Compound context
Research peptides and Canadian regulation: the Health Canada advisory and research-use labels
A source-based summary of the April 2026 Health Canada advisory on unauthorized injectable peptides — what a "research use only" label does and doesn't mean, and where procurement responsibility sits for a Canadian laboratory.
Jul 18, 20267 min readRead - Compound context
BPC-157 in Canada: research identity, documentation, and regulatory context
A source-based guide to BPC-157 identity, its research status, the Canadian regulatory and anti-doping context, and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 18, 20267 min readRead - Compound context
TB-500 in Canada: research identity, documentation, and regulatory context
A source-based guide to TB-500 identity, its research status, the Canadian and anti-doping regulatory context, and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 18, 20267 min readRead - Compound context
GHK-Cu in Canada: research identity, documentation, and regulatory context
A source-based guide to GHK-Cu identity as a copper tripeptide, its research status, the Canadian regulatory context, and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 18, 20266 min readRead - Compound context
Ipamorelin in Canada: research identity, documentation, and regulatory context
A source-based guide to Ipamorelin identity as a growth-hormone-secretagogue pentapeptide, its development history, the Canadian and anti-doping regulatory context, and what a lot-specific CoA does and doesn't establish.
Jul 18, 20266 min readRead - Compound context
CJC-1295 in Canada: research identity, documentation, and regulatory context
A source-based guide to CJC-1295 identity as a long-acting GHRH analogue, its development history, the Canadian and anti-doping regulatory context, and what a lot-specific CoA does and doesn't establish.
Jul 18, 20266 min readRead - Compound context
MOTS-c in Canada: research identity, documentation, and regulatory context
A source-based guide to MOTS-c identity as a mitochondrial-derived peptide, its research status, the Canadian and anti-doping regulatory context, and what a lot-specific CoA does and doesn't establish.
Jul 18, 20266 min readRead - Compound context
NAD+ in Canada: research identity, documentation, and regulatory context
A source-based guide to NAD+ identity as a coenzyme (not a peptide), its research status, the Canadian regulatory context, and what a lot-specific CoA does and doesn't establish for a Canadian laboratory.
Jul 18, 20266 min readRead - Documentation
How to read a peptide certificate of analysis
A Certificate of Analysis packs several distinct tests onto one page. Here's what each field actually verifies — and what none of them tell you on their own.
Jul 16, 20267 min readRead - Methods
HPLC purity vs. mass-spec identity: what each test proves
Purity, identity, and sterility are three different claims backed by three different tests. Here's how to read a chromatogram without conflating them.
Jul 16, 20267 min readRead - Logistics
Lyophilized peptide storage and cold-chain handling
Lyophilization buys stability, not immunity. What threatens a lyophilized peptide vial in transit — and how to check whether a shipment held its cold chain.
Jul 16, 20266 min readRead - Sourcing
Sourcing research peptides in Canada: a due-diligence checklist
What to ask a research peptide supplier for before ordering: lot-specific documentation, testing evidence, traceability, and what domestic sourcing changes.
Jul 16, 20266 min readRead - Reference
Reading a peptide product catalogue: naming, purity grades, and package sizes
What a compound code, a blend name, and a package-size suffix actually encode — and what "research grade" means, and doesn't mean, as a label.
Jul 16, 20266 min readRead - Compound context
Retatrutide in Canada: research identity, documentation, and regulatory context.
A source-based guide to Retatrutide identity, clinical-research references, COA limits, and the Canadian regulatory warning around unauthorized peptide products.
Jul 15, 20267 min readRead - Documentation
Peptide integrity: why storage conditions dictate assay reproducibility
Peptides are chemically unstable reagents. Their value relies on structural fidelity over time.
Jun 12, 20264 min readRead - Methods
HPLC purity vs. potency — what 99% actually means.
A peptide can test at 99% HPLC and still bind half as well as expected. Here's the difference between chromatographic purity and bioactive potency, and why you need both.
Apr 12, 20266 min readRead - Logistics
Lyophilized peptide shipping: what customers should verify.
Shipment and storage claims should stay tied to lot-specific documentation, product labels, and actual carrier conditions — not blanket cold-chain promises.
Mar 28, 20266 min readRead - Documentation
Lot documentation and laboratory SOP boundaries.
Vitatide publishes research-use documentation, but preparation and handling procedures are determined by the receiving laboratory.
Feb 9, 20265 min readRead